SPDR S&P Biotech ETF
755 hedge funds and large institutions have $9.15B invested in SPDR S&P Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 252 increasing their positions, 253 reducing their positions, and 97 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
755
Holders Change
-19
Holders Change %
-2.45%
% of All Funds
10.98%
Holding in Top 10
18
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-21.74%
% of All Funds
0.26%
New
88
Increased
252
Reduced
253
Closed
97
Calls
$1.59B
Puts
$2.95B
Net Calls
-$1.36B
Net Calls Change
+$358M
Top Buyers
| 1 |
JPMorgan Chase & Co
New York
|
$1.14B |
| 2 |
Goldman Sachs
New York
|
$1.11B |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
$490M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
$832M |
| 5 |
Two Sigma Advisers
New York
|
$89.8M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
$6.3M |
| 2 |
Citigroup
New York
|
$673M |
| 3 |
CHP
Castle Hook Partners
New York
|
$19.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
$281M |
| 5 |
Morgan Stanley
New York
|
$595M |
